Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Letter to the Editor

Functional cure of chronic hepatitis B encounters resmetirom

Nai-Bin Yang, Wai-Kay Seto, Ming-Hua Zheng

Clin Mol Hepatol. 2024;30(3):580-581. Published online April 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0301

View: 2538 Download: 106 Web of Science: 2 Crossref: 2

Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(3):577-579. Published online March 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0157

View: 2857 Download: 171 Web of Science: 7 Crossref: 5

Original Article

Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis

Juchul Hwang, Hyeyoung Hwang, Hyunjae Shin, Bo Hyun Kim, Seong Hee Kang, Jeong-Ju Yoo, Mi Young Choi, Dong eun Lee, Dae Won Jun, Yuri Cho

Clin Mol Hepatol. 2024;30(3):561-576. Published online June 3, 2024

DOI: https://doi.org/10.3350/cmh.2023.0384

View: 3653 Download: 152 Web of Science: 4 Crossref: 7

Novel role of MHC class II transactivator in hepatitis B virus replication and viral counteraction

Mehrangiz Dezhbord, Seong Ho Kim, Soree Park, Da Rae Lee, Nayeon Kim, Juhee Won, Ah Ram Lee, Dong-Sik Kim, Kyun-Hwan Kim

Clin Mol Hepatol. 2024;30(3):539-560. Published online May 14, 2024

DOI: https://doi.org/10.3350/cmh.2024.0060 Correction in: Clin Mol Hepatol 2024;30(4):1060

View: 3615 Download: 267 Web of Science: 6 Crossref: 3

Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy

Qi Wang, Qingfa Bu, Zibo Xu, Yuan Liang, Jinren Zhou, Yufeng Pan, Haoming Zhou, Ling Lu

Clin Mol Hepatol. 2024;30(3):515-538. Published online May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0107

View: 4364 Download: 293 Web of Science: 2 Crossref: 3

Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study

Moon Haeng Hur, Dong Hyeon Lee, Jeong-Hoon Lee, Mi-Sook Kim, Jeayeon Park, Hyunjae Shin, Sung Won Chung, Hee Jin Cho, Min Kyung Park, Heejoon Jang, Yun Bin Lee, Su Jong Yu, Sang Hyub Lee, Yong Jin Jung, Yoon Jun Kim, Jung-Hwan Yoon

Clin Mol Hepatol. 2024;30(3):500-514. Published online May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0055

View: 3203 Download: 179 Web of Science: 2 Crossref: 3

Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study

Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, Seulggie Choi, Sun Jae Park, Hye Jun Kim, Gyeongsil Lee, Joung Sik Son, Heejoon Jang, Dong Hyeon Lee, Meng Sha, Lei Chen, Won Kim, Sang Min Park

Clin Mol Hepatol. 2024;30(3):487-499. Published online May 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0145

View: 3974 Download: 273 Web of Science: 2 Crossref: 4

Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy

Pei-Chien Tsai, Chung-Feng Huang, Ming-Lun Yeh, Meng-Hsuan Hsieh, Hsing-Tao Kuo, Chao-Hung Hung, Kuo-Chih Tseng, Hsueh-Chou Lai, Cheng-Yuan Peng, Jing-Houng Wang, Jyh-Jou Chen, Pei-Lun Lee, Rong-Nan Chien, Chi-Chieh Yang, Gin-Ho Lo, Jia-Horng Kao, Chun-Jen Liu, Chen-Hua Liu, Sheng-Lei Yan, Chun-Yen Lin, Wei-Wen Su, Cheng-Hsin Chu, Chih-Jen Chen, Shui-Yi Tung, Chi‐Ming Tai, Chih-Wen Lin, Ching-Chu Lo, Pin-Nan Cheng, Yen-Cheng Chiu, Chia-Chi Wang, Jin-Shiung Cheng, Wei-Lun Tsai, Han-Chieh Lin, Yi-Hsiang Huang, Chi-Yi Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chung, Ming-Jong Bair, Ming-Lung Yu, T-COACH Study Group

Clin Mol Hepatol. 2024;30(3):468-486. Published online April 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0038

View: 4027 Download: 191 Web of Science: 9 Crossref: 3

Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease

Yiyuan Zheng, Lina Zhao, Zhekun Xiong, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Yugang Fu, Simin Gu, Chong Chen, Jiacheng Li, Yingying Zhu, Jing Liu, Fengbin Liu, Yong Li

Clin Mol Hepatol. 2024;30(3):449-467. Published online April 16, 2024

DOI: https://doi.org/10.3350/cmh.2024.0047

View: 5260 Download: 407 Web of Science: 7 Crossref: 7

Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis

Harry Crane, Guy D. Eslick, Cameron Gofton, Anjiya Shaikh, George Cholankeril, Mark Cheah, Jian-Hong Zhong, Gianluca Svegliati-Baroni, Alessandro Vitale, Beom Kyung Kim, Sang Hoon Ahn, Mi Na Kim, Simone I Strasser, Jacob George

Clin Mol Hepatol. 2024;30(3):436-448. Published online April 16, 2024

DOI: https://doi.org/10.3350/cmh.2024.0109

View: 6181 Download: 312 Web of Science: 11 Crossref: 14

Ischemia-free liver transplantation improves the prognosis of recipients using functionally marginal liver grafts

Shuai Wang, Xiaohong Lin, Yunhua Tang, Yichen Liang, Min Zhang, Zhonghao Xie, Yiwen Guo, Yuqi Dong, Qiang Zhao, Zhiyong Guo, Dongping Wang, Xiaoshun He, Weiqiang Ju, Maogen Chen

Clin Mol Hepatol. 2024;30(3):421-435. Published online April 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0139

View: 3087 Download: 149 Web of Science: 1 Crossref: 2

Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma

Chun-Ting Ho, Elise Chia-Hui Tan, Pei-Chang Lee, Chi-Jen Chu, Yi-Hsiang Huang, Teh-Ia Huo, Yu-Hui Su, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su

Clin Mol Hepatol. 2024;30(3):406-420. Published online April 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0103

View: 3895 Download: 195 Web of Science: 10 Crossref: 10

Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment

Do Seon Song, Hee Yeon Kim, Young Kul Jung, Tae Hyung Kim, Hyung Joon Yim, Eileen L Yoon, Ki Tae Suk, Jeong-ju Yoo, Sang Gyune Kim, Moon Young Kim, Young Chang, Soung Won Jeong, Jae Young Jang, Sung-Eun Kim, Jung-Hee Kim, Jung Gil Park, Won Kim, Jin Mo Yang, Dong Joon Kim, Korean Acute-on-Chronic Liver Failure (KACLiF) study group, Ashok Kumar Choudhury, Vinod Arora, Shiv Kumar Sarin, APASL ACLF Research Consortium (AARC) for APASL ACLF working party

Clin Mol Hepatol. 2024;30(3):388-405. Published online April 11, 2024

DOI: https://doi.org/10.3350/cmh.2023.0563

View: 3303 Download: 122 Web of Science: 4 Crossref: 3

Phase 1 trial of the safety, pharmacokinetics, and antiviral activity of EDP-514 in untreated viremic chronic hepatitis B patients

Man-Fung Yuen, Wan-Long Chuang, Cheng-Yuan Peng, Wen-Juei Jeng, Wei-Wen Su, Ting-Tsung Chang, Chi-Yi Chen, Yao-Chun Hsu, Guy De La Rosa, Alaa Ahmad, Ed Luo, Annie L. Conery

Clin Mol Hepatol. 2024;30(3):375-387. Published online March 26, 2024

DOI: https://doi.org/10.3350/cmh.2023.0535

View: 3548 Download: 124 Web of Science: 1 Crossref: 1

Multiomics profiling of buffy coat and plasma unveils etiology-specific signatures in hepatocellular carcinoma

Jiwon Hong, Jung Woo Eun, Geum Ok Baek, Jae Youn Cheong, Seryoung Park, Soon Sun Kim, Hyo Jung Cho, Su Bin Lim

Clin Mol Hepatol. 2024;30(3):360-374. Published online March 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0042

View: 4986 Download: 346 Web of Science: 4 Crossref: 4

Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study

Young Eun Chon, Dong Yun Kim, Mi Na Kim, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Sang Hoon Ahn, Yeonjung Ha, Joo Ho Lee, Kwan Sik Lee, Beodeul Kang, Jung Sun Kim, Hong Jae Chon, Do Young Kim

Clin Mol Hepatol. 2024;30(3):345-359. Published online March 12, 2024

DOI: https://doi.org/10.3350/cmh.2023.0553

View: 4789 Download: 431 Web of Science: 11 Crossref: 8

Review

Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication

Chung-Feng Huang, Manar Hijaze Awad, Meital Gal-Tanamy, Ming-Lung Yu

Clin Mol Hepatol. 2024;30(3):326-344. Published online April 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.0155

View: 3574 Download: 166 Web of Science: 6 Crossref: 5

Liver sinusoidal endothelial cell: An important yet often overlooked player in the liver fibrosis

Jiaorong Qu, Le Wang, Yufei Li, Xiaojiaoyang Li

Clin Mol Hepatol. 2024;30(3):303-325. Published online February 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0022

View: 5825 Download: 336 Web of Science: 8 Crossref: 10

Snapshot

Immunopathogenesis of liver fibrosis in steatotic liver disease

Chaerin Woo, Won-Il Jeong

Clin Mol Hepatol. 2024;30(2):299-302. Published online February 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0113

View: 3464 Download: 122

Reply to Correspondence

Correspondence on Letter regarding “Both liver parenchymal and non-parenchymal cells express JCAD proteins under various circumstances”

Byoung Kuk Jang

Clin Mol Hepatol. 2024;30(2):297-298. Published online April 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0210

View: 2390 Download: 44

Correspondence

Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring

Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu

Clin Mol Hepatol. 2024;30(2):293-296. Published online February 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0101

View: 2160 Download: 67

Reply to: “Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis”

Haeryoung Kim, Sook-Hyang Jeong

Clin Mol Hepatol. 2024;30(2):291-292. Published online March 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0180

View: 2485 Download: 46 Web of Science: 1 Crossref: 1

Correspondence on Editorial regarding “Identification of signature gene set as highly accurate determination of MASLD progression”

Sungju Jung, Sumin Yoon, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo

Clin Mol Hepatol. 2024;30(2):287-290. Published online February 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0136

View: 2688 Download: 77 Crossref: 1

In response to: Steatotic liver disease-know your enemies

Michael H. Le, Linda Henry, Mindie H. Nguyen

Clin Mol Hepatol. 2024;30(2):284-286. Published online February 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0108

View: 2424 Download: 45

Correspondence on Letter regarding “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study”

Hideki Fujii, Michihiro Iwaki, Yoshihiro Kamada

Clin Mol Hepatol. 2024;30(2):281-283. Published online April 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0214

View: 2575 Download: 45 Crossref: 1

Both liver parenchymal and non-parenchymal cells express JCAD protein under various circumstances

Li Xie, Li Zhang, Hui Chen, Yong-Yu Yang, Jian Wu

Clin Mol Hepatol. 2024;30(2):279-280. Published online March 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0191

View: 2644 Download: 69 Web of Science: 1 Crossref: 1

Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research

Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu

Clin Mol Hepatol. 2024;30(2):276-278. Published online April 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0220

View: 2448 Download: 43

Correspondence on Letter regarding “Toward hepatitis C virus elimination using artificial intelligence”

Ming-Ying Lu, Ming-Lung Yu

Clin Mol Hepatol. 2024;30(2):274-275. Published online March 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0152

View: 2868 Download: 44 Web of Science: 2 Crossref: 2

Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply

Hyeyeon Hong, Jonggi Choi

Clin Mol Hepatol. 2024;30(2):272-273. Published online February 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0123

View: 2433 Download: 83 Web of Science: 1 Crossref: 1

Letter to the Editor

Letter regarding “Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation”

Yun-Fan Liaw

Clin Mol Hepatol. 2024;30(2):269-271. Published online January 31, 2024

DOI: https://doi.org/10.3350/cmh.2024.0064

View: 2339 Download: 50 Web of Science: 1 Crossref: 1

Viewed By 6974	MAFLD: How is it different from NAFLD?
Viewed By 6225	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 5317	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5150	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4664	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 298	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 266	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 170	MAFLD: How is it different from NAFLD?
Cited By 92	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 88	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Topics